Phenylpropanolamine

Overview

Phenylpropanolamine (PPA), sold under many brand names, is a sympathomimetic agent used as a decongestant and appetite suppressant. It was once common in prescription and over-the-counter cough and cold preparations. The medication is taken orally.[1–6] WP

Side effects of phenylpropanolamine include increased heart rate and blood pressure. Rarely, PPA has been associated with hemorrhagic stroke. PPA acts as a norepinephrine releasing agent, indirectly activating adrenergic receptors. As such, it is an indirectly acting sympathomimetic. It was once thought to act as a sympathomimetic with additional direct agonist action on adrenergic receptors, but this proved wrong. Chemically, phenylpropanolamine is a substituted amphetamine and is closely related to ephedrine, pseudoephedrine, amphetamine, and cathinone. It is usually a racemic mixture of the (1R,2S)- and (1S,2R)-enantiomers of β-hydroxyamphetamine and is also known as dl-norephedrine.[1–4][6–16] WP

Phenylpropanolamine was first synthesized around 1910 and its effects on blood pressure were characterized around 1930. It was introduced as medicine by the 1930s. It was withdrawn from many markets starting in 2000 after learning that it was associated with increased risk of hemorrhagic stroke. It was previously available both over-the-counter and by prescription. Phenylpropanolamine is available for both human and/or veterinary use in some countries.[4][15][17–20] WP

Uses, dosage and effects

Medical uses

Phenylpropanolamine is used as a decongestant to treat nasal congestion. It has also been used to suppress appetite and promote weight loss in the treatment of obesity and has shown effectiveness for this indication.[7][8][21][22][23] WP

Available forms

Phenylpropanolamine was previously available in the United States over-the-counter and in certain combination drug forms by prescription. One such example of the latter was a combination of phenylpropanolamine and chlorpheniramine, which dually contained decongestant and antihistamine effects, marketed by Tutag as 'Vernate'. These forms have all been discontinued in the U.S., although phenylpropanolamine remains available in some countries.[18][19][20] WP

Veterinary use

Phenylpropanolamine is available for use in veterinary medicine. It is used to control urinary incontinence in dogs.[20][24][25] WP

In June 2024, the US Food and Drug Administration (FDA) approved Phenylpropanolamine hydrochloride chewable tablets for the control of urinary incontinence due to a weakening of the muscles that control urination (urethral sphincter hypotonus) in dogs. This is the first generic phenylpropanolamine hydrochloride chewable tablets for dogs.[26][27][28] WP

Urinary incontinence happens when a dog loses its ability to control when it urinates. Urinary incontinence due to urethral sphincter hypotonus can happen as dogs age and as the dog's muscle in its urethra (the tube that leads from the dog's bladder to outside its body) weakens and loses control over its ability to hold urine.[26] WP

Phenylpropanolamine hydrochloride chewable tablets contain the same active ingredient (phenylpropanolamine hydrochloride) in the same concentration and dosage form as the approved brand name drug product, Proin chewable tablets, which were first approved in August 2011. In addition, the FDA determined that Phenylpropanolamine hydrochloride chewable tablets contain no inactive ingredients that may significantly affect the bioavailability of the active ingredient.[26] WP

Risks and side effects

Side effects

Phenylpropanolamine produces sympathomimetic effects and can cause side effects such as increased heart rate and blood pressure. It has been associated rarely with incidence of hemorrhagic stroke.[6–10][17] WP

Certain drugs increase the chances of déjà vu occurring in the user, resulting in a strong sensation that an event or experience currently being experienced has already been experienced in the past. Some pharmaceutical drugs, when taken together, have also been implicated in the cause of déjà vu. The Journal of Clinical Neuroscience reported the case of an otherwise healthy male who started experiencing intense and recurrent sensations of déjà vu upon taking the drugs amantadine and phenylpropanolamine together to relieve flu symptoms. He found the experience so interesting that he completed the full course of his treatment and reported it to the psychologists to write up as a case study. Because of the dopaminergic action of the drugs and previous findings from electrode stimulation of the brain, it was speculated that déjà vu occurs as a result of hyperdopaminergic action in the mesial temporal areas of the brain.[29][30] WP

Interactions

Interactions

There has been very little research on drug interactions with phenylpropanolamine. In one study, phenylpropanolamine taken with caffeine was found to quadruple caffeine levels. In another study, phenylpropanolamine reduced theophylline clearance by 50%.[5] WP

Pharmacology

Pharmacodynamics

Phenylpropanolamine acts primarily as a selective norepinephrine releasing agent. It also acts as a dopamine releasing agent with around 10-fold lower potency. The stereoisomers of the drug have only weak or negligible affinity for α- and β-adrenergic receptors.[13] WP⚠ A table follows this text in the source and is not copied here. Open the source to see it.

Phenylpropanolamine was originally thought to act as a direct agonist of adrenergic receptors and hence to act as a mixed acting sympathomimetic, However, phenylpropanolamine was subsequently found to show only weak or negligible affinity for these receptors and has been instead characterized as exclusively an indirectly acting sympathomimetic. It acts by inducing norepinephrine release and thereby indirectly activating adrenergic receptors.[3][11][12][13][15][16] WP

Many sympathetic hormones and neurotransmitters are based on the phenethylamine skeleton, and function generally in "fight or flight" type responses, such as increasing heart rate, blood pressure, dilating the pupils, increased energy, drying of mucous membranes, increased sweating, and a significant number of additional effects. WP⚠ Wikipedia itself has flagged this text: citation needed.

Phenylpropanolamine has relatively low potency as a sympathomimetic. It is about 100 to 200 times less potent than epinephrine (adrenaline) or norepinephrine (noradrenaline) in its sympathomimetic effects, although responses are variable depending on tissue.[15] WP

Absorption

Phenylpropanolamine is readily- and well-absorbed with oral administration. Immediate-release forms of the drug reached peak levels about 1.5 hours (range 1.0 to 2.3 hours) following administration. Conversely, extended-release forms of phenylpropanolamine reach peak levels after 3.0 to 4.5 hours. The pharmacokinetics of phenylpropanolamine are linear across an oral dose range of 25 to 100 mg. Steady-state levels of phenylpropanolamine are achieved within 12 hours when the drug is taken once every 4 hours. There is 62% accumulation of phenylpropanolamine at steady state in terms of peak levels, whereas area-under-the-curve levels are not increased with steady state.[5][31][32][33] WP

Distribution

The volume of distribution of phenylpropanolamine is 3.0 to 4.5 L/kg. Levels of phenylpropanolamine in the brain are about 40% of those in the heart and 20% of those in the lungs. The hydroxyl group of phenylpropanolamine at the β carbon increases its hydrophilicity, reduces its permeation through the blood–brain barrier, and limits its central nervous system (CNS) effects. Hence, phenylpropanolamine crosses into the brain only to some extent, has only weak CNS effects, and most of its effects are peripheral. In any case, phenylpropanolamine can produce amphetamine-like psychostimulant effects at very high doses. Phenylpropanolamine is more lipophilic than structurally related sympathomimetics with hydroxyl groups on the phenyl ring like epinephrine (adrenaline) and phenylephrine and has greater brain permeability than these agents.[5][8][15][16][31][33] WP

The plasma protein binding of phenylpropanolamine is approximately 20%. However, it has been said that no recent studies have substantiated this value.[5][33] WP

Metabolism

Phenylpropanolamine is not substantially metabolized. It also does not undergo significant first-pass metabolism. Only about 3 to 4% of an oral dose of phenylpropanolamine is metabolized. Metabolites include hippuric acid (via oxidative deamination of the side chain) and 4-hydroxynorephedrine (via para-hydroxylation). The methyl group at the α carbon of phenylpropanolamine blocks metabolism by monoamine oxidases (MAOs). Phenylpropanolamine is also not a substrate of catechol O-methyltransferase. The hydroxyl group at the β carbon of phenylpropanolamine also helps to increase metabolic stability.[5][8][31][32][33] WP

Elimination

Approximately 90% of a dose of phenylpropanolamine is excreted in the urine unchanged within 24 hours. About 4% of excreted material is in the form of metabolites.[5][31][32][33] WP

The elimination half-life of immediate-release phenylpropanolamine is about 4 hours, with a range in different studies of 3.7 to 4.9 hours. The half-life of extended-release phenylpropanolamine has ranged from 4.3 to 5.8 hours.[5][31][32] WP

The elimination of phenylpropanolamine is dependent on urinary pH. At a more acidic urinary pH, the elimination of phenylpropanolamine is accelerated and its half-life and duration are shortened, whereas at more basic urinary pH, the elimination of phenylpropanolamine is reduced and its half-life and duration are extended. Urinary acidifying agents like ascorbic acid and ammonium chloride can increase the excretion of and thereby reduce exposure to amphetamines including phenylpropanolamine, whereas urinary alkalinizing agents including antacids like sodium bicarbonate as well as acetazolamide can reduce the excretion of these agents and thereby increase exposure to them.[5][33][34][35] WP

Total body clearance of phenylpropanolamine has been reported to be 0.546 L/h/kg, while renal clearance was 0.432 L/h/kg.[5] WP

Miscellaneous

As phenylpropanolamine is not extensively metabolized, it would probably not be affected by hepatic impairment. Conversely, there is likely to be accumulation of phenylpropanolamine with renal impairment due to its dependence on urinary excretion.[5] WP

Norephedrine is a minor metabolite of amphetamine and methamphetamine, as shown below. It is also a minor metabolite of ephedrine and a major metabolite of cathinone.[5][31][33] WP

History

History

Phenylpropanolamine was first synthesized in the early 20th century, in or around 1910. It was patented as a mydriatic in 1913. The pressor effects of phenylpropanolamine were characterized in the late 1920s and the 1930s. Phenylpropanolamine was first introduced for medical use by the 1930s.[4][15][17] WP

In the United States, phenylpropanolamine is no longer sold due to an increased risk of haemorrhagic stroke. In a few countries in Europe, however, it is still available either by prescription or sometimes over-the-counter. In Canada, it was withdrawn from the market on 31 May 2001. It was voluntarily withdrawn from the Australian market by July 2001. In India, human use of phenylpropanolamine and its formulations was banned on 10 February 2011, but the ban was overturned by the judiciary in September 2011.[10][36–39] WP

Legal status

Names

Phenylpropanolamine is the generic name of the drug and its INN (International Nonproprietary Name), BAN (British Approved Name), and DCF (Dénomination Commune Française), while phenylpropanolamine hydrochloride is its USAN (United States Adopted Name) and BANM (British Approved Name) in the case of the hydrochloride salt. It is also known by the synonym norephedrine.[1][2][3][18] WP

Brand names of phenylpropanolamine include Acutrim, Appedrine, Capton Diet, Control, Dexatrim, Emagrin Plus A.P., Glifentol, Kontexin, Merex, Monydrin, Mydriatine, Prolamine, Propadrine, Propagest, Recatol, Rinexin, Tinaroc, and Westrim, among many others. It has also been used in combinations under brand names including Allerest, Demazin, Dimetapp, and Sinarest, among others.[1][2][18] WP

Availability

Phenylpropanolamine is available for medical and veterinary use in some countries.[2][18] WP

Exercise and sports

There has been interest in phenylpropanolamine as a performance-enhancing drug in exercise and sports. However, clinical studies suggest that phenylpropanolamine is not effective in this regard. Phenylpropanolamine is not on the World Anti-Doping Agency (WADA) list of prohibited substances as of 2024.[31][40][41] WP

Legal status

In Sweden, phenylpropanolamine is still available in prescription decongestants; Phenylpropanolamine is also still available in Germany. It is used in some polypill medications like Wick DayMed capsules.[42] WP

In the United Kingdom, phenylpropanolamine was available in many "all in one" cough and cold medications which usually also feature paracetamol (also known as acetaminophen) or another analgesic and caffeine and could also be purchased on its own. It is no longer approved for human use, however, and a European Category 1 Licence is required to purchase or acquire phenylpropanolamine for academic or research use. WP

In the United States, the Food and Drug Administration (FDA) issued a public health advisory recommending against the use of the drug in November 2000. In this advisory, the FDA requested but did not require that all drug companies discontinue marketing products containing phenylpropanolamine. The agency estimates that phenylpropanolamine caused between 200 and 500 strokes per year among 18-to-49-year-old users. In 2005, the FDA removed phenylpropanolamine from over-the-counter sale and removed its "generally recognized as safe and effective" (GRASE) status. Under the 2020 CARES Act, it requires FDA approval before it can be marketed again, effectively banning the drug, even as a prescription.[43][44][45] WP

Because of its potential use in amphetamine manufacture, phenylpropanolamine is controlled by the Combat Methamphetamine Epidemic Act of 2005. However, It is still available for veterinary use in dogs as a treatment for urinary incontinence. WP

Internationally, an item on the agenda of the 2000 Commission on Narcotic Drugs session called for including the stereoisomer norephedrine in Table I of United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.[46] WP

Drugs containing phenylpropanolamine were banned in India on 27 January 2011. On 13 September 2011, Madras High Court revoked a ban on the manufacture and sale of pediatric drugs phenylpropanolamine and nimesulide.[47][48] WP

Chemistry

Formula

C9H13NO PC

Molar mass (g/mol)

151.21 PC

IUPAC name (computed by PubChem)

2-amino-1-phenylpropan-1-ol PC

SMILES

CC(C(C1=CC=CC=C1)O)N PC

InChIKey

DLNKOYKMWOXYQA-UHFFFAOYSA-N PC

PubChem CID

4786

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 2014
2. Other Schweizerischer Apotheker-Verein. Index Nominum 2000: International Drug Directory. 2000
3. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 2012
4. Journal / agency Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006. doi:10.2165/00002018-200629040-00001 · PMID 16569079
5. Journal / agency Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy. 1993. doi:10.1002/j.1875-9114.1993.tb02780.x · PMID 7507589
6. Journal / agency Salerno SM, Jackson JL, Berbano EP. The impact of oral phenylpropanolamine on blood pressure: a meta-analysis and review of the literature. J Hum Hypertens. August 2005. doi:10.1038/sj.jhh.1001869 · PMID 15944721
7. Journal / agency Johnson DA, Hricik JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy. 1993. doi:10.1002/j.1875-9114.1993.tb02779.x · PMID 7507588
8. Journal / agency O'Donnell SR. Sympathomimetic vasoconstrictors as nasal decongestants. Med J Aust. March 1995. doi:10.5694/j.1326-5377.1995.tb139882.x · PMID 7534374
9. Journal / agency Aaron CK. Sympathomimetics. Emerg Med Clin North Am. August 1990. doi:10.1016/S0733-8627(20)30256-X · PMID 2201518
10. Journal / agency Yoon BW, Bae HJ, Hong KS, Lee SM, Park BJ, Yu KH, Han MK, Lee YS, Chung DK, Park JM, Jeong SW, Lee BC, Cho KH, Kim JS, Lee SH, Yoo KM. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology. January 2007. doi:10.1212/01.wnl.0000250351.38999.f2 · PMID 17210897
11. Journal / agency Rothman RB, Baumann MH. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006. doi:10.2174/156802606778249766 · PMID 17017961
12. Journal / agency Rothman RB, Baumann MH. Targeted screening for biogenic amine transporters: potential applications for natural products. Life Sci. December 2005. doi:10.1016/j.lfs.2005.09.001 · PMID 16202429
13. Journal / agency Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther. October 2003. doi:10.1124/jpet.103.053975 · PMID 12954796
14. Other Lemke TL, Williams DA. Foye's Principles of Medicinal Chemistry. 2008
15. Journal / agency Johnson DA. Pharmacology and safety of phenylpropanolamine. Drug Development Research. 1991. doi:10.1002/ddr.430220302
16. Journal / agency Bravo EL. Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension. March 1988. doi:10.1161/01.hyp.11.3_pt_2.ii7 · PMID 3280497
17. Journal / agency Mersfelder TL. Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. Cleve Clin J Med. March 2001. doi:10.3949/ccjm.68.3.208 · PMID 11263849
18. Other Phenylpropanolamine. 24 March 2015
19. Journal / agency Drugs@FDA: FDA-Approved Drugs
20. Journal / agency Search Results for phenylpropanolamine
21. Journal / agency Coulter AA, Rebello CJ, Greenway FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. July 2018. doi:10.1007/s40265-018-0946-y · PMID 30014268 · PMC6095132
22. Journal / agency Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005. doi:10.2165/00003495-200565100-00006 · PMID 15977970
23. Journal / agency Greenway F, Herber D, Raum W, Herber D, Morales S. Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. Obes Res. July 1999. doi:10.1002/j.1550-8528.1999.tb00420.x · PMID 10440593
24. Other Gupta RC. Veterinary Toxicology: Basic and Clinical Principles. 23 April 2012
25. Other Riviere JE, Papich MG. Veterinary Pharmacology and Therapeutics. 17 March 2009
26. Journal / agency FDA Approves Phenylpropanolamine Hydrochloride Tablets for Dogs. 11 June 2024
27. Journal / agency Recent Animal Drug Approvals. 2 December 2024
28. Journal / agency fda.gov
29. Journal / agency Taiminen T, Jääskeläinen SK. Intense and recurrent déjà vu experiences related to amantadine and phenylpropanolamine in a healthy male. Journal of Clinical Neuroscience. September 2001. doi:10.1054/jocn.2000.0810 · PMID 11535020
30. Journal / agency Bancaud J, Brunet-Bourgin F, Chauvel P, Halgren E. Anatomical origin of déjà vu and vivid 'memories' in human temporal lobe epilepsy. Brain. February 1994. doi:10.1093/brain/117.1.71 · PMID 8149215
31. Journal / agency Bouchard R, Weber AR, Geiger JD. Informed decision-making on sympathomimetic use in sport and health. Clin J Sport Med. July 2002. doi:10.1097/00042752-200207000-00003 · PMID 12131054
32. Journal / agency Gentile DA, Friday GA, Skoner DP. Management of allergic rhinitis: antihistamines and decongestants. Immunology and Allergy Clinics of North America. 2000. doi:10.1016/S0889-8561(05)70152-1
33. Journal / agency Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. Biopharm Drug Dispos. 1989. doi:10.1002/bdd.2510100102 · PMID 2647163
34. Journal / agency Głowacka K, Wiela-Hojeńska A. Pseudoephedrine—Benefits and Risks. Int J Mol Sci. May 2021. doi:10.3390/ijms22105146 · PMID 34067981 · PMC8152226
35. Journal / agency Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Human Psychopharmacology: Clinical and Experimental. 1997. doi:10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U
36. Other Advisories, Warnings and Recalls – 2001. 7 January 2009
37. Other Alert Phenylpropanolamine. 7 March 2006
38. Other Drugs Banned In India
39. Other Madras High Court revokes ban on manufacture and sale of paediatric drugs nimesulide and PPA – India Medical Times
40. Journal / agency Jones G. Caffeine and other sympathomimetic stimulants: modes of action and effects on sports performance. Essays Biochem. 2008. doi:10.1042/BSE0440109 · PMID 18384286
41. Other The Prohibited List. 1 January 2024
42. Other Rinexin in Farmaceutiska Specialiteter i Sverige
43. Journal / agency Phenylpopanolamine Advisory. 6 November 2000
44. Journal / agency Phenylpropanolamine (PPA) Information Page – FDA moves PPA from OTC. 23 December 2005
45. Journal / agency Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act
46. Harm reduction site Implementation of the international drug control treaties: changes in the scope of control of substances. 6–15 March 2000
47. Other Unsafe Drugs- nimesulide, Cisapride, Phenylpropanolamine Banned. 27 January 2011
48. Other Madras High Court Revokes Ban on Manufacture and Sale PPA. 13 September 2011

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.